Sequenom (SQNM) Reports In-Line Q4 EPS

Sequenom (NASDAQ: SQNM) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $27.8 million versus the consensus estimate of $27.8 million.

Fourth quarter total accessions of 42,200, up from 41,000 in Q3 2015
Fourth quarter noninvasive prenatal test (NIPT) accessions of 37,300, up from 35,500 in Q3 2015

For earnings history and earnings-related data on Sequenom (SQNM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• MP Materials seen largely insulated after China export-control move
• Pfizer lung cancer drug misses survival goal in Phase 3 trial